This study, which represents the largest-scale, prospective, multicenter clinical investigation globally in this field, included paired tissue and plasma samples for NGS analysis from 149 patients with EGFR-mutant advanced NSCLC at the first-line treatment failure of osimertinib in a real-world setting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.